CAS: 1000787-75-6; 5-((6-(2,4-Bis(Trifluoromethyl)Phenyl)Pyridazin-3-yl)Methyl)-2-(2-Fluorophenyl)-5H-Imidazo[4,5-C]Pyridine
- 英文名称5-((6-(2,4-Bis(Trifluoromethyl)Phenyl)Pyridazin-3-yl)Methyl)-2-(2-Fluorophenyl)-5H-Imidazo[4,5-C]Pyridine
- 中文名称5-((6-(2,4-双(三氟甲基)苯基)吡嗪-3-基)甲基)-2-(2-氟苯基)-5H-咪唑并[4,5-c]吡啶
- IUPAC名称5-((6-(2,4-bis(trifluoromethyl)phenyl)pyridazin-3-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine
- 其它别名3-[2,4-Bis(Trifluoromethyl)Phenyl]-6-{[2-(2-Fluorophenyl)-5H-Imidazo[4,5-C]Pyridin-5-Yl]Methyl}Pyridazine; 5H-Imidazo(4,5-C)Pyridine, 5-((6-(2,4-Bis(Trifluoromethyl)Phenyl)-3-Pyridazinyl)Methyl)- 2-(2-Fluorophenyl)-; N
- CAS编号1000787-75-6
- MFCD编号:MFCD18251457
- FDA UNII编号:5NOK5X389M
- 分子式:C25H14F7N5分子量:517.41
- 产品CID: 3428
- 产品分类生物化工 → 生化试剂 → 激动剂抑制剂
物理性质
MSDS等安全信息
上下游产品
5-((6-氯哒嗪-3-基)甲基)-2-(2-氟苯基)-5H-咪唑并[4,5-C]吡啶 5-[6-Chloro-Pyridazin-3-Ylmethyl]-2-(2-Fluoro-Phenyl)-5H-Imidazo[4,5-C]Pyridine 1000787-76-73-(2,4-Bis-Trifluoromethyl-Phenyl)-6-Chloromethyl-Pyridazine 1099778-81-0
合成工艺路线路线简述
- 合成目标产物 5-((6-(2,4-Bis(Trifluoromethyl)Phenyl)Pyridazin-3-yl)Methyl)-2-(2-Fluorophenyl)-5H-Imidazo[4,5-C]Pyridine 主要起始原料 3-Chloro-6-Chloromethylpyridazine
- (文献来源)合成步骤主要原料 3-Chloro-6-Chloromethylpyridazine
📜3-氯-6-甲基哒嗪置于四(三苯基膦)钯,三氯异氰尿酸,Sodium Carbonate,Sodium Hydroxide体系中,用 乙二醇二甲醚,氯仿,水,N,N-二甲基甲酰胺 用作溶剂,化学反应 76.5H,反应生成5-((6-(2,4-双(三氟甲基)苯基)吡嗪-3-基)甲基)-2-(2-氟苯基)-5H-咪唑并[4,5-C]吡啶
参考文献:Methods For Treating Hcv
标题:Methods For Treating Hcv
摘要:这项发明涉及治疗丙型肝炎病毒感染的治疗分子组合.本发明涉及方法,用途,给药方案和组合物.
专利信息
专利号:US-2021290651-A1
优先权日:2020-03-20
标 题:Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
专利号:US-2021308117-A1
优先权日:2020-03-20
标 题 :Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
专利号:US-2021315880-A1
优先权日:2020-03-20
标 题 :Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
专利号:WO-2021189018-A9
优先权日:2020-03-20
标 题 :Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Ma B, Yamaguchi K, Fukuoka M, Kuwata K. Logical design of anti-prion agents using NAGARA. Biochem Biophys Res Commun. 2016 Jan 22;469(4):930-5. doi: 10.1016/j.bbrc.2015.12.106. Epub 2015 Dec 24. doi: 10.1016/j.antiviral.2015.05.011. Epub 2015 May 30. doi: 10.1128/AAC.03699-14. Epub 2014 Sep 22.
4: De Clercq E. Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochem Pharmacol. 2014 Jun 15;89(4):441-52. doi: 10.1016/j.bcp.2014.04.005. Epub 2014 Apr 13. doi: 10.1002/hep.27053. Epub 2014 May 28. doi: 10.1128/AAC.00487-13. Epub 2013 Aug 12.
7: Winquist J, Abdurakhmanov E, Baraznenok V, Henderson I, Vrang L, Danielson UH. Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase. Antiviral Res. 2013 Mar;97(3):356-68. doi: 10.1016/j.antiviral.2012.12.027. Epub 2013 Jan 7. doi: 10.1016/j.cld.2012.09.004. Review. doi: 10.1371/journal.pone.0039163. Epub 2012 Jun 13.
合成参考文献
参考文献:10.1186/1471-2105-12-294
摘要:Liu Q, Zhou H, Liu L, Chen X, Zhu R, Cao Z. Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study. BMC Bioinformatics. 2011 Jul 20;12():294.
📝 需求与反馈
尽可能描述清楚需求与问题信息
